Target intelligence / Profile preview

TTC28 antisense RNA 1 (TTC28-AS1)

Target: TTC28-AS1
Molecular classification: Long non-coding RNA (lncRNA), Antisense RNA, Non-protein coding RNA

Overview

TTC28 antisense RNA 1 (TTC28-AS1) is a long non-coding antisense RNA gene transcribed from the TTC28 gene locus on chromosome 10 (also reported at chromosome 22 in some references, but major sources agree on chromosome 10)[2][3]. TTC28-AS1 is non-protein coding and functions as an antisense RNA, likely involved in regulating the expression of neighboring or overlapping genes by interacting with microRNAs and chromatin-modifying complexes[1][5]. Recent studies implicate TTC28-AS1 in attenuating high glucose-induced cellular damage in renal tubular epithelial cells via modulation of the miR-320a/CD2AP axis, with implications in diabetic nephropathy[1]. Multi-lncRNA signatures that include TTC28-AS1 have been correlated with prognosis in childhood acute lymphoblastic leukemia and bladder cancer, indicating its potential as a prognostic biomarker[1]. However, there are no known drugs that directly target TTC28-AS1, and its exact biochemical functions and broader clinical relevance remain under-investigated as of the latest research.

Other names: KIAA1648TTC28-ASTTC28ASdJ353E16.2TTC28 antisense RNA (non-protein coding)TTC28 antisense RNA 1 (non-protein coding)

Biological functions

Gene expression regulationPotential post-transcriptional regulation through miRNA interaction[1]Putative involvement in cellular responses to high glucose, particularly in kidney epithelial cells[1]Potential association with epithelial–mesenchymal transition and cancer-related signaling[1]

Disease associations

Diabetic nephropathy[1]Childhood acute lymphoblastic leukemia (as a prognostic biomarker)[1]Bladder cancer (as a prognostic biomarker)[1]Glioma susceptibility (according to database associations)[3]

Biomarkers

Component of prognostic lncRNA signatures in acute lymphoblastic leukemia and bladder cancer[1]

Beyond the preview

Go deeper on TTC28 antisense RNA 1 (TTC28-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TTC28 antisense RNA 1 (TTC28-AS1).

Explore the full profile